Everolimus 10 mg daily

DRUG2 trials

Sponsors

European Institute of Oncology, Fudan University

Conditions

Breast Cancer FemalesPancreatic Neuroendocrine Tumour MetastaticTriple Negative Breast Cancer (TNBC)

Phase 2

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

CompletedNCT02305810

European Institute of OncologyPancreatic Neuroendocrine Tumour Metastatic

Start: 2013-09-30End: 2018-06-30Updated: 2018-11-07

Phase 3

Adjuvant Intensification for LAR

Not yet recruitingNCT07407517

Fudan UniversityBreast Cancer Females, Triple Negative Breast Cancer (TNBC)

Start: 2026-02-01End: 2033-02-01Target: 904Updated: 2026-02-12

Related Papers

Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

Cancers2022-09-1510 citations